Genmab GAAP EPS of $15.37, revenue of $3.72B misses by $50M; initiates FY26 outlook
Source: SeekingAlpha
2026-02-17 23:53:12 ET
More on Genmab
- Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript
- Genmab A/S 2025 Q4 - Results - Earnings Call Presentation
- Genmab: Darzalex Growth Fuels Rally, Upside Is Tight
- Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma
- Genmab ends development of late-stage oncology asset acasunlimab
Read the full article on Seeking Alpha
For further details see:
Genmab GAAP EPS of $15.37, revenue of $3.72B misses by $50M; initiates FY26 outlook
Genmab
NASDAQ: GNMSF
GNMSF Trading
0.0% G/L:
$290 Last:
7 Volume:
$290 Open:
GNMSF Latest News
GNMSF Stock Data
$20,431,984,318
64,554,266
N/A
758
N/A
Biotechnology & Life Sciences
Healthcare
DK
Valby
